Listing of Claims:

1. **(currently amended)** A method for statistically significantly potentiating the activity of a SN-38 prodrug, the method comprising co-administering an oligonucleotide with the prodrug, wherein the oligonucleotide does not have two 5' and four 3' 2-O-methylribonucleosides and wherein the oligonucleotide does not have the sequence of SEQ ID NO: 1.

2. **(currently amended)** The method according to claim 1, wherein the prodrug is an ester or an amide of an ~~active compound~~ SN-38.

3. **(canceled)**

4. **(canceled)**

5. **(currently amended)** The method according to claim [4] 1, wherein the prodrug is ~~Camptosar~~ irinotecan.

6. **(currently amended)** The method according to ~~any one of claims 1-5~~ claim 1, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

7. **(canceled)**

8. **(previously presented)** The method according to claim 6, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

9. **(previously presented)** The method according to claim 8, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.

10. **(currently amended)** A method for statistically significantly potentiating the activity of [a] an SN-38 prodrug, the method comprising co-administering an oligonucleotide with the prodrug, wherein the ~~the~~ oligonucleotide is administered before the prodrug.

11. **(currently amended)** The method according to claim 10, wherein the prodrug is an ester or an amide of an ~~active compound~~ SN-38.

12. **(canceled)**

13. **(canceled)**

14. **(currently amended)** The method according to claim ~~13~~ 10, wherein the prodrug is ~~Camptosar~~ irinotecan.

15. **(currently amended)** The method according to ~~any one of claims 10-14~~ claim 10, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

16. **(canceled)**

17. **(original)** The method according to claim 15, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

18. **(previously presented)** The method according to claim 17, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.

19. **(currently amended)** A method for statistically significantly potentiating the activity of [a] an SN-38 prodrug, the method comprising co-administering an oligonucleotide with the prodrug,

wherein the prodrug is present in an amount that would not be therapeutically effective in the absence of the oligonucleotide.

20. **(currently amended)** The method according to claim 19, wherein the prodrug is an ester or an amide of an ~~active compound~~ SN-38.

21. **(canceled)**

22. **(canceled)**

23. **(currently amended)** The method according to claim 19, wherein the prodrug is ~~Camptosar~~ irinotecan.

24. **(currently amended)** The method according to ~~any one of claims 19-23~~ claim 19, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

25. **(canceled)**

26. **(previously presented)** The method according to claim 24, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

27. **(previously presented)** The method according to claim 26, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.

28. **(new)** The method of claim 1, wherein statistical significance is determined using an unpaired t-test and p is less than or equal to 0.08 when the method is compared to a control in which either no prodrug is administered or no oligonucleotide is administered.

29. **(new)** The method according to claim 2, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

30. **(new)** The method according to claim 5, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

31. **(new)** The method according to claim 11, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

32. **(new)** The method according to claim 14, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

33. **(new)** The method according to claim 20, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

34. **(new)** The method according to claim 23, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

35. **(new)** The method of claim 1, wherein the prodrug is a CPT-11 analog.

36. **(new)** The method of claim 10, wherein the prodrug is a CPT-11 analog.

37. **(new)** The method of claim 19, wherein the prodrug is a CPT-11 analog.